Methotrexaat Accord

Methotrexate, the active ingredient in Methotrexaat Accord, is an antimetabolite (folate antagonist) presented as a sterile solution for intra‑arterial, intramuscular and intravenous use. It is employed in the management of certain cancers, autoimmune disorders and severe skin disease in adult patients.

GNH USA supplies Methotrexaat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate acts as a folate pathway inhibitor and is indicated for several oncologic and immune‑mediated conditions. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: induces remission by interfering with malignant cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumor control as part of combination regimens. - Breast cancer: used in high‑dose protocols to enhance cytotoxic effect.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring shortly after administration. - Fatigue: persistent tiredness affecting daily activities. - Mucositis: inflammation and ulceration of the oral mucosa. - Alopecia: temporary hair loss. - Elevated liver enzymes: mild hepatic enzyme rise detectable on labs. - Skin rash: mild erythematous eruptions.

Serious or Rare Side Effects: - Bone marrow suppression: leading to anemia, leukopenia or thrombocytopenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe infection: opportunistic infections due to immunosuppression. - Hepatotoxicity: significant liver injury or fibrosis. - Renal failure: acute kidney injury from precipitation of drug crystals. - Secondary malignancies: rare development of therapy‑related cancers.

Patients receiving Methotrexaat Accord should be monitored closely for safety concerns. - Blood count monitoring: perform complete blood counts before each dose and periodically during therapy. - Liver function assessment: check hepatic enzymes regularly and adjust therapy if elevations occur. - Renal function evaluation: assess serum creatinine and adjust dosing in impaired clearance. - Pregnancy risk: avoid use in pregnant women unless benefits outweigh risks; advise effective contraception. - Infection vigilance: educate patients to report fever, sore throat or other infection signs promptly. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methotrexaat Accord can interact with several medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - NSAIDs: increase methotrexate plasma levels and risk of renal toxicity. - Penicillins and sulfonamides: potentiate bone marrow suppression. - Live vaccines: heightened risk of infection due to immunosuppression. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Proton pump inhibitors: can reduce renal clearance, raising toxicity.

Moderate Interactions (Monitor Closely): - Trimethoprim: may increase hematologic toxicity. - Azathioprine: additive immunosuppressive effect. - Allopurinol: can elevate methotrexate concentrations. - Cholestyramine: may reduce oral absorption if used concurrently. - Phenytoin: may alter hepatic metabolism of methotrexate.